Ocugen, Inc. announced that the Data and Safety Monitoring Board has approved the continuation of the second phase of the Phase 1/2 OCU410 ArMaDa clinical trial for treating geographic atrophy (GA) ...

Ocugen OCGN is pushing a modifier gene therapy platform across several retinal diseases where current options are limited, ...

Regardless of dosing regimen, patients treated with ranibizumab had a 43% higher incidence of GA, which was a statistically significant increase compared with bevacizumab. The ranibizumab group had ...

(RTTNews) - Annexon, Inc.(ANNX), on Thursday announced presentations highlighting the potential of its investigational drug ANX007 for the treatment of geographic atrophy or GA, a form of advanced dry ...

OCU410 has a very favorable safety and tolerability profile No serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular ...

Please provide your email address to receive an email when new articles are posted on . Science Corporation reported positive preliminary results of a clinical trial examining its Prima retinal ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The top retina articles on Healio this year included ...